Sirtex Medical Inc. Expands U.S. Operations to Accommodate Increased Demand for SIR-Spheres® Microspheres

Wednesday 15 August 2012
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today expansion of U.S. operations with the placement of additional sales, marketing, and functional support staff in Massachusetts and across the country.

Sirtex produces SIR- Spheres® microspheres, the only fully FDA PMA-approved microsphere radiation therapy for the treatment of colorectal liver metastases. The expansion follows the announcement of record growth for Sirtex in the U.S. in terms of dose sales for SIR-Spheres microspheres.  Product for the U.S. market is currently produced at the company’s manufacturing facilities in Wilmington, Massachusetts

Sirtex’s expansion is part of the company’s previously announced global growth plan that began in the U.S. in July 2010, with additions in July 2011, and the latest annual installment in 2012.

“Sirtex continues to reach new milestones related to the number of U.S. dose sales, and we look forward to continuing to expand the business and build awareness for SIR-Spheres microspheres so more patients have access to this beneficial cancer treatment,” said Michael Mangano, president of Sirtex Medical Inc. “This latest expansion will allow us to accommodate current and future growth by addressing the increased demand for SIR-Spheres microspheres in treatment centers across the country and effectively reaching more patients diagnosed with colorectal liver tumors.”

For more information visit  www.sirtex.com.

About Selective Internal Radiation Therapy using SIR-Spheres microspheres

Selective Internal Radiation Therapy (SIRT), also known as radioembolization, is a proven technology for inoperable liver cancer that delivers doses of radiation directly to the site of tumors. In a minimally invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

Clinical studies have confirmed that patients with metastatic colorectal cancer treated with SIR- Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.

SIR-Spheres microspheres are approved for use in Australia, the United States of America (FDA PMA-approval), and the European Union (CE Mark) and additionally supplied in countries such as Hong Kong, Malaysia, Singapore, Thailand, Taiwan, India, Israel, and Turkey. Available at more than 400 treatment centers, over 20,000 doses of SIR-Spheres microspheres have been supplied worldwide.

For more information, visit www.sirtex.com.

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

 

###

Media Contact

Kassidie Blackstock

Phone:    919-457-0749

Email:    Kassidie.Blackstock@fleishman.com

 

Doc Code 601-U-0812


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage